Andrew A. Radin, twoXAR

Andrew A. Radin Andrew Radin is Co-Founder and Chief Executive Officer of twoXAR, an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships. Andrew developed the company's proprietary algorithm and leads product development. Prior to co-founding twoXAR, He held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.

Sessions

10:05 AM - 10:35 AM

AI Applications for Identifying New Drug Candidates

Your CEO knows the company needs to adopt AI/ML technology, but they don't want to get involved in the details.  You now have the budget, but you need to produce an ROI.  What are your options when it comes to using AI tools to identify new drug candidates?  AI has the potential to become an indispensable tool but only if the near-term ROI is realized.  What questions do you need to ask to get this right and make a difference in speed, cost and outcomes?

Moderator

Speakers

  • Adam West

    Adam West Director, Research Data Sciences and Engineering Eli Lilly and Company


Download Latest Agenda